Recent News

• 11.10.2025 - CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.08.2025 - CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
• 10.10.2025 - CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
• 10.01.2025 - CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
• 09.25.2025 - Vertex Announces Key Advancements Across Kidney Portfolio
• 09.25.2025 - Vertex Announces Key Advancements Across Kidney Portfolio
• 09.23.2025 - Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
• 09.23.2025 - Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
• 09.23.2025 - Bank of America Global Healthcare Conference London
• 09.23.2025 - Bank of America Global Healthcare Conference London

Recent Filings

• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 8-K Current report
• 10.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 144 Report of proposed sale of securities